{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:28Z","timestamp":1793923948287,"version":"4.8.0"},"reference-count":46,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche S.p.A."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>There is limited evidence on the economic implications of assessing patients\u2019 access to personalised treatments through Comprehensive Genomic Profiling (CGP) and Molecular Tumour Board (MTB), prompting the need to analyse their impact on the cost of the cancer diagnostic journey (from hospital admission to MTB evaluation) and accessibility to personalised therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective observational cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Patients discussed from April 2020 to September 2021 by the institutional MTB operating at Fondazione IRCCS Istituto Nazionale Tumori of Milan, an Italian centre of excellence in oncology pertaining to the national health system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>676 patients focused on: non-small cell lung cancer (NSCLC), cholangiocarcinoma (CCA), pancreatic carcinoma (PC) and gastro-oesophageal carcinoma (GEC). We defined two different scenarios: (1) patients tested with small Next-Generation Sequencing (NGS) panels (\u226460 biomarkers) vs (2) patients tested with comprehensive panels (&gt;60 biomarkers).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>We measured (1) patients\u2019 eligibility to personalised therapies based on genomic data obtained using targeted somatic NGS panels, (2) MTB cost and the overall diagnostic journey cost and (3) the cost to find a patient eligible to access personalised treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tumour profiling with comprehensive NGS panels improved patients\u2019 eligibility to personalised therapies compared with small panels (NSCLC: 39% comprehensive panel vs 37% small panel; CCA: 43% vs 17%; PC: 35% vs 3%; GEC: 40% vs 0%). The overall diagnostic journey cost per patient was between 3.2K and 7.4K (NSCLC: 7.4K comprehensive panel vs 6.4K small panel; CCA: 4.9K vs 3.7K; PC: 5.8K vs 4.5K; GEC: 4.2K vs 3.2K). MTB discussion accounted for only 2\u20133% of the diagnostic journey cost per patient (around 113\u20ac\/patient). The cost to find patient eligible for personalised treatments varied significantly according to panel size and tumour setting (NSCLC: 5K comprehensive panel vs 2.8K small panel; CCA: 4.4K vs 4.4K; PC: 5.5K vs 27K; GEC: 5.2K vs not measurable since none of the patients analysed with small NGS panels were eligible).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>MTB discussion of genomic data obtained with NGS comprehensive panels significantly increases patient eligibility to targeted therapies and optimise the cost to find a patient eligible to personalised treatments, mainly for CCA, PC and GEC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-099134","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:14:30Z","timestamp":1747718070000},"page":"e099134","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study"],"prefix":"10.1136","volume":"15","author":[{"given":"Valentina","family":"De Micheli","sequence":"first","affiliation":[{"name":"Life Sciences Division, Business Integration Partners S.p.A, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Conca","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Lucia","family":"Rabsiun Aramburu","sequence":"additional","affiliation":[{"name":"Life Sciences Division, Business Integration Partners S.p.A, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Baggi","sequence":"additional","affiliation":[{"name":"Life Sciences Division, Business Integration Partners S.p.A, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vingiani","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Duca","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Perrone","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tamborini","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lorenzini","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Busico","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Capone","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Proto","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vernieri","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siranoush","family":"Manoukian","sequence":"additional","affiliation":[{"name":"Unit of Medical Genetics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gancitano","sequence":"additional","affiliation":[{"name":"Roche SpA, Monza, Lombardy, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ferrario","sequence":"additional","affiliation":[{"name":"Roche SpA, Monza, Lombardy, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Franzini","sequence":"additional","affiliation":[{"name":"Life Sciences Division, Business Integration Partners S.p.A, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-7172","authenticated-orcid":false,"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Jommi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi del Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2025101814431976000_15.5.e099134.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025101814431976000_15.5.e099134.2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025101814431976000_15.5.e099134.3","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.2217\/fon-2021-0286","article-title":"Molecular tests and target therapies in oncology: recommendations from the Italian workshop","volume":"17","author":"Pinto","year":"2021","journal-title":"Future Oncol"},{"key":"2025101814431976000_15.5.e099134.4","doi-asserted-by":"crossref","DOI":"10.3390\/genes15081036","article-title":"A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology","volume":"15","author":"Clark","year":"2024","journal-title":"Genes (Basel)"},{"key":"2025101814431976000_15.5.e099134.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00824-4"},{"key":"2025101814431976000_15.5.e099134.6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-025-00795-x","article-title":"Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection","volume":"25","author":"Bruhm","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2025101814431976000_15.5.e099134.7","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00249-0"},{"key":"2025101814431976000_15.5.e099134.8","doi-asserted-by":"crossref","first-page":"103525","DOI":"10.1016\/j.critrevonc.2021.103525","article-title":"Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study","volume":"169","author":"Pisapia","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025101814431976000_15.5.e099134.9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejca.2023.03.027","article-title":"Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study","volume":"187","author":"Normanno","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025101814431976000_15.5.e099134.10","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00067","article-title":"Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care","volume":"7","author":"Vingiani","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025101814431976000_15.5.e099134.11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular Tumor Boards in Clinical Practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"key":"2025101814431976000_15.5.e099134.12","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10040252","article-title":"Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting","volume":"10","author":"VanderWalde","year":"2020","journal-title":"J Pers Med"},{"key":"2025101814431976000_15.5.e099134.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02512-0","article-title":"Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer","volume":"41","author":"Ciliberto","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2025101814431976000_15.5.e099134.14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41568-022-00529-3","article-title":"The coming decade in precision oncology: six riddles","volume":"23","author":"Wahida","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2025101814431976000_15.5.e099134.15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/03008916211062266","article-title":"The molecular tumor board: a tool for the governance of precision oncology in the real world","volume":"108","author":"Incorvaia","year":"2022","journal-title":"Tumori"},{"key":"2025101814431976000_15.5.e099134.16","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00132","article-title":"Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance","volume":"6","author":"Walters","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2025101814431976000_15.5.e099134.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"2025101814431976000_15.5.e099134.18","unstructured":"Decreto Ministero Salute (GU n. 190 from 16.08.2023) . Istituzione dei Molecular tumor board e individuazione dei centri specialistici per l\u2019esecuzione dei test per la profilazione genomica estesa Next generation sequencing (NGS). Italy: Decreto Ministero Salute (GU n. 190 from 16.08.2023), 2023."},{"key":"2025101814431976000_15.5.e099134.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.014"},{"key":"2025101814431976000_15.5.e099134.20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"2025101814431976000_15.5.e099134.21","unstructured":"AIOM-Registri Tumori Italiani-SIAPEC-PASSI-PASSI D\u2019ARGENTO-ONS-Fondazione AIOM . I numeri del cancro 2022. 2022."},{"key":"2025101814431976000_15.5.e099134.22","unstructured":"Nomenclatore tariffario specialistica ambulatoriale Lombardia, 2021. 2021."},{"key":"2025101814431976000_15.5.e099134.23","unstructured":"Nomenclatore tariffario interventi chirurgici Lombardia, 2021. 2021."},{"key":"2025101814431976000_15.5.e099134.24","unstructured":"FASDAC Fondo Assistenza Sanitaria Dirigenti Aziende Commerciali . Nomenclatore tariffario 2021. 2021."},{"key":"2025101814431976000_15.5.e099134.25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.12669\/pjms.342.14245","article-title":"Cost analysis of medical device spare parts","volume":"34","author":"Bektemur","year":"2018","journal-title":"Pak J Med Sci"},{"key":"2025101814431976000_15.5.e099134.26","unstructured":"Jefferson T , Cerbo M , Chiarolla E , et al . HTA report - next generation sequencing (NGS). AGENAS, 2017."},{"key":"2025101814431976000_15.5.e099134.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0618-7"},{"key":"2025101814431976000_15.5.e099134.28","unstructured":"Delibera Giunta regionale 3 giugno 2024 . XII\/2442 Istituzione del \u00abMolecular Tumor Board\u00bb regionale ed individuazione dei Servizi di medicina di laboratorio specialistici per l\u2019esecuzione dei test per la profilazione genomica estesa Next Generation Sequencing (NGS) ai sensi del d.m. salute del 30 maggio 2023. Italy, 2024."},{"key":"2025101814431976000_15.5.e099134.29","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025101814431976000_15.5.e099134.30","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000339","article-title":"Relevance of a molecular tumour board (MTB) for patients\u2019 enrolment in clinical trials: experience of the Institut Curie","volume":"3","author":"Basse","year":"2018","journal-title":"ESMO Open"},{"key":"2025101814431976000_15.5.e099134.31","doi-asserted-by":"crossref","first-page":"NP30","DOI":"10.1177\/03008916221132589","article-title":"Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?","volume":"108","author":"Garajov\u00e1","year":"2022","journal-title":"Tumori"},{"key":"2025101814431976000_15.5.e099134.32","doi-asserted-by":"crossref","first-page":"100928","DOI":"10.1016\/j.esmoop.2023.100928","article-title":"70MO Genomic profiling to expand precision cancer medicine in the real world: the ROME trial","volume":"8","author":"Botticelli","year":"2023","journal-title":"ESMO Open"},{"key":"2025101814431976000_15.5.e099134.33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/gim.2016.174","article-title":"The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial","volume":"19","author":"Pag\u00e8s","year":"2017","journal-title":"Genet Med"},{"key":"2025101814431976000_15.5.e099134.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.015"},{"key":"2025101814431976000_15.5.e099134.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-021-00338-8"},{"key":"2025101814431976000_15.5.e099134.36","unstructured":"IQN Path, ECPC, EFPIA . Unlocking the potential of precision medicine in Europe. 2021."},{"key":"2025101814431976000_15.5.e099134.37","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/PO.20.00495","article-title":"Clinical Outcomes of Molecular Tumor Boards: A Systematic Review","volume":"5","author":"Larson","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025101814431976000_15.5.e099134.38","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/PO.21.00210","article-title":"Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer","volume":"5","author":"Huang","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025101814431976000_15.5.e099134.39","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.2217\/fon-2021-0688","article-title":"Precision oncology: a clinical and patient perspective","volume":"17","author":"Lassen","year":"2021","journal-title":"Future Oncol"},{"key":"2025101814431976000_15.5.e099134.40","unstructured":"Scambia G , Curigliano G , Sapino A , et al . Ministero della Salute Consiglio Superiore di Sanit\u00e0 Sessione LIII (2022-2025) Sezione I Pianificazione di sistema ed economica, Innovazione e ricerca, sviluppo di nuovi modelli di servizio nel SSN \u2018Proposta di regolamentazione per l\u2019appropriatezza dell\u2019utilizzo dei Test Multigenici NGS predittivi e prognostici nella pratica clinica\u2019 2022."},{"key":"2025101814431976000_15.5.e099134.41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2023.03.041","article-title":"Do more targets allow more cancer treatments, or not?","volume":"187","author":"Marchetti","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025101814431976000_15.5.e099134.42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/03008916211069412","article-title":"Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities","volume":"109","author":"De Giglio","year":"2023","journal-title":"Tumori"},{"key":"2025101814431976000_15.5.e099134.43","first-page":"26","article-title":"Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs","volume":"7","author":"Cicchetti","year":"2020","journal-title":"Glob Reg Health Technol Assess"},{"key":"2025101814431976000_15.5.e099134.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-021-07255-w","article-title":"The economic impact of compassionate use of medicines","volume":"21","author":"Jommi","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2025101814431976000_15.5.e099134.45","doi-asserted-by":"crossref","DOI":"10.1186\/s40545-023-00570-z","article-title":"Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case","volume":"16","author":"Tarantola","year":"2023","journal-title":"J Pharm Policy Pract"},{"key":"2025101814431976000_15.5.e099134.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0969-2"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-099134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:43:31Z","timestamp":1760823811000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-099134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,16]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2025-099134"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-099134","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}